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Introduction
Chemokines and chemokine receptors provide direc-
tional cues for leukocyte migration and concomitant-
ly induce the recruitment of T cells into sites of inflam-
mation (1, 2). This process is particularly important in
autoimmune diseases such as diabetes (3). Initial stud-
ies in this area have emphasized that chemokine recep-
tor expression is tightly regulated on Th cells, and that
Th cell subsets express restricted receptors for
chemokines (4–8). For example, Th1 cells express the
chemokine receptors CXCR3 and CCR5, while CCR3,
CCR4, and CCR8 are found on Th2 cells. It was report-
ed that the CCR4/macrophage-derived chemokine
(MDC) axis plays a key role in the long-term recruit-
ment of Th2 cells, indicating in vivo significance of dis-
tinct CCR4 expression on Th2 cells (9). However, recent
observations suggest that CCR4 expression is not
restricted to highly polarized Th2 cells. T cells express-
ing cutaneous lymphocyte–associated antigen can pro-
duce both IFN-γ and IL-4, yet more than 95% of these
cells express high levels of CCR4 (10). Furthermore, a
significant proportion of cells expressing cutaneous
lymphocyte–associated antigen coexpress CCR4 and
the Th1-associated receptors CXCR3 (35%) and CCR5
(50%). While these findings highlight the complexity of
CCR4 expression by T cell subsets, the role played by
CCR4 in the physiological and pathophysiological
migration of T cells in vivo is unappreciated.
We have investigated the role of CCR4 in the migra-
tory capacity of T cells during pathogenic autoimmu-
nity in NOD mice, a model for human insulin-depend-
ent diabetes mellitus in which Th1 cells mediate the
destruction of pancreatic β cells. Here we demonstrate
that CCR4-bearing T cells are in vivo pathogenic pop-
ulations participating in the development of tissue-
driven autoimmune reactions.
Methods
Mice. NOD/shi, NOD/Lt-scid/scid, C57BL/6, and BDC2.5
NOD (11) were obtained from The Scripps Research Insti-
tute. NOD-scid and BDC2.5 NOD mice were used at 8–10
weeks and 6–8 weeks of age, respectively.
Generation of transgenic mice. MDC-transgenic (MDC-
TG) NOD mice were raised and maintained in specific
pathogen–free quarters at The Scripps Research Insti-
tute. Use of the human insulin promoter resulted in
the generation of founder mice that selectively
expressed soluble MDC in the pancreatic β cells, which
was confirmed by immunohistochemistry.
Ab’s. mAb’s were generated as previously described
(12). B cell hybridomas secreting these mAb’s were
purchased from American Type Culture Collection
(Manassas, Virginia, USA). They included CD3 (145-
2C11, hamster IgG), CD16/32 (FcγIII/II, 2.4G2, rat
IgG2b), CD28 (37.51, hamster IgG), and Vβ4 (KT4,
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rat IgG2b). The mAb’s specific for CD4 (L3T4, GK1.5,
rat IgG2b), CD8 (Lyt-2, 53-6-7, rat IgG2a), CD11b
(Mac-1, M1/70, rat IgG2b), CD11c (integrin αx chain,
HL3, hamster IgG), CD25 (3C7, IL-2 receptor α chain,
rat IgG2b), CD44 (pgp-1, IM7, rat IgG2b), CD45RB
(16A, rat IgG2a), CD54 (ICAM-1, 3E2, hamster IgG),
CD62L (L-selectin, Mel-14, rat IgG2a), CD69 (very
early activation marker, H1.2F3, rat IgG1), CD95
(Fas, Jo2, hamster IgG), CCR5 (C34-3448, rat IgG2c),
B220 (CD45, RA3-6B2, rat IgG2a), and MHC class I
(H-2Kd, SF1-1.1, mouse IgG2a) were obtained from
Pharmingen (La Jolla, California, USA). Antibodies to
MDC (rabbit polyclonal), thymus- and activation-reg-
ulated chemokine (TARC) (hamster monoclonal),
and CCR4 (mouse monoclonal) were obtained from
ICOS Corp. Polyclonal Ab’s against mouse MDC were
prepared by immunizing New Zealand white rabbits
with synthetic murine MDC (kindly provide by Ian
Clarke-Lewis, University of British Columbia, Van-
couver, British Columbia, Canada) conjugated to key-
hole limpet hemocyanin. The IgG was purified from
rabbit sera. This polyclonal Ab was demonstrated to
recognize MDC in ELISA at a dilution of 1:500,000.
The specificity of this Ab was evaluated by ELISA and
shown not to recognize a panel of CC and CXC
chemokines, including murine TARC. Neutralizing
activity to mouse MDC was shown in chemotaxis
assays using L1.2 cells expressing murine CCR4 (data
not shown). The endotoxin content of this reagent
was below 0.05 endotoxin units/ml, the limit of sen-
sitivity of the assay (Pyrogent; BioWhittaker Inc.,
Walkersville, Maryland, USA) (13). The anti-CCR4
mAb was generated using L1.2/CCR4-expressing cells
as antigen and was screened for specific recognition
of human CCR4 transfectants by FACS (14). We fur-
ther confirmed a high cross-reactivity between
human and murine CCR4 by a functional migration
assay. FACS-sorted CCR4-positive cells specifically
responded to the CCR4 ligand murine MDC (Figure
1a), indicating that the anti-CCR4 mAb specifically
recognized putative murine CCR4. T cells that did
not stain with the CCR4 mAb responded to murine
MDC. The anti-human CCR4 Ab was found to cross-
react with murine CCR4 of T cells from NOD (Figure
1) and C57BL/6 mice (15) but not BALB/c mice,
which was mouse-strain immunized (14). In addition,
this anti-human CCR4 Ab showed a unique expres-
sion pattern of CCR4 on leukocyte memory subsets
(CD45RBlowCD62LlowCD27+CD44high) of NOD mice
(Figure 2) that was comparable to the expression pat-
tern of human leukocytes (16). Furthermore, expres-
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Figure 1
Functional responsiveness of CCR4+ T cells to the murine CCR4 lig-
and MDC. (a) Chemotactic response of CCR4+CD4+ T cells to
murine chemokines. The migration of FACS-sorted CCR4-negative
and -positive BDC2.5 CD4+ T cells to murine MDC (15 ng/ml) was
studied in a Transwell assay. The assay was also carried out in the
presence of anti-human CCR4 and isotype control mAb’s (left). In
addition, the chemotactic function of the various murine
chemokines MDC, TARC, SLC, and MCP-1 was evaluated on CCR4-
expressing BDC2.5 CD4+ T cells (right). Data representing the per-
centage of migrating sorted cells (left) or CCR4+CD4+ T cells are
expressed as the mean of triplicates ± SEM. Left graph: black bar,
CCR4–; white bar, CCR4+; light gray bar, CCR4+/IgG1; dark gray bar,
CCR4+/anti-CCR4 mAb. Right graph: black bar, murine MCP-1;
white bar, murine MDC; light gray bar, murine TARC; dark gray bar,
murine SLC. These data indicate that the human CCR4 mAb cross-
reacts with murine CCR4. (b) Expression of CCR4 and CCR5 and
activation molecules CD25 and CD69 in leukocyte subsets 8-week-
old NOD/shi mice and their modulation through the activation or
polarization of BDC2.5 CD4+ T cells. (c) Cytokine profile of polar-
ized Th subsets. To assess the polarization of Th1 and Th2 cells in
vitro, we have examined the double intracellular cytokine staining of
the polarized Th effectors generated by short-term culture of high-
ly purified naive BDC2.5 T cell populations. We demonstrated that
Th1 and Th2 cells were well polarized and differentiated (n = 5).
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sion of CCR4 was inducible by activation (Figure 1b
and Figure 3a).
Purification of CD4+ T cells. CD4+ T cells were purified
from splenocytes of 6- to 8-week-old BDC2.5 or 16- to
18-week-old diabetic NOD mice using the StemSep
CD4 isolation kit (StemCell Technologies Inc., Van-
couver, British Columbia, Canada).
Sorting of CCR4-positive and -negative cells and characteriza-
tion. For the isolation and characterization of CCR4-pos-
itive cells, purified CD4+ T cells were incubated with
CD16/32 (FcγIII/II) for 10 minutes to remove Fc back-
ground staining, and then stained with anti-CCR4 mAb
(mouse IgG1) and other Ab’s for indicated cell surface
markers. Stained cells were analyzed and sorted on a
FACStar Plus (Becton, Dickinson and Co., Franklin
Lakes, New Jersey, USA). Sorted cells were used for a
chemotactic assay against the murine CCR4 ligand
MDC or immediately activated with concanavalin A
(Con A; 2.5 µg/ml) or glutamic acid decarboxylase
(GAD65) (10 µg/ml) for 2–4 days in a coculture using
irradiated spleen cells as antigen-presenting cells (APCs).
The culture supernatants were harvested and analyzed
for cytokine production. For the study of CCR4 expres-
sion kinetics, CCR4-negative cells were stimulated with
media or anti-CD3 and anti-CD28 Ab’s.
Chemotaxis assays. Cell migration assays were per-
formed as previously described (17). The sorted CCR4-
negative and -positive BDC2.5 CD4+ T cells were
adapted for 1 hour at 37°C in an incubator with 5%
CO2. Briefly, 2.0 × 105 cells were resuspended in 200 µl
of RPMI 1640 medium containing 1.0% FCS and
transmigrated through bare filter Transwell inserts
with 5-µm pores (Corning-Costar Corp., Cambridge,
Massachusetts, USA) for 6 hours. For blocking exper-
iments, CCR4+ T cells were preincubated with anti-
CCR4 mAb (106 cells/µg) for 15 minutes at 37°C
before being added to the Transwell inserts. Migrated
cells were counted by FACS analysis of scatter-gated
lymphocytes. Chemotaxis was performed in the pres-
ence of optimized ligands (15–50 ng/ml), including
murine MDC (CCL22), TARC (CCL17), secondary
lymphoid-tissue chemokine (SLC, also known as
CCL21) (all obtained from R&D Systems Inc., Min-
neapolis, Minnesota, USA), and monocyte chemoat-
tractant protein-1 (MCP-1) from Pharmingen. The
percentage of migrating cells was determined as the
number of cells migrating to chemokines (lower cham-
ber) less the number of cells migrating to medium
(lower chamber), divided by the total number of cells.
Three independent experiments were performed.
Generation of Th subsets. Purified resting CD4+ cells were
isolated from BDC2.5 spleens. Th1 and Th2 cells were
induced by culture of CD4+ T cells for 4 days in 25 ml of
RPMI 1640 supplemented with 7% FCS. Flasks were
coated with anti-CD3 mAb (145-2C11 clone) and
washed before the addition of CD4+ T cells (5 × 105/ml).
The cultures were supplemented with recombinant 
IL-2 (rIL-2) and anti-CD28 (37.51 clone). To generate
Th1 cells, cultures were supplemented with rIL-12 and
anti–IL-4 mAb (11B11 clone). To induce Th2 cells, rIL-4
and anti–IFN-γ mAb (46A2 clone) were added. After 60
hours, the cells were expanded in medium containing
rIL-2. To confirm polarization, double intracellular
staining of IFN-γ and IL-4 was performed.
Adoptive transfer. For the diabetic onset study using
splenocyte transfer, newly diagnosed diabetic (16–18
weeks old) or nondiabetic (8 weeks old) MDC-TG and
non-TG NOD littermates were used as splenocyte
donors. NOD-scid females 8–10 weeks old were inject-
ed intravenously with 2 × 107 donor splenocytes in sus-
pension. For the T cell homing study, 2 × 106 CCR4-
sorted CD4+ T cells were injected into 8- to 10-week-old
NOD-scid females.
Effect of anti-MDC Ab on disease onset and insulitis. In a
blocking experiment, 8- to 10-week-old NOD-scid
females were injected intravenously with 1.5 × 107
splenocytes from diabetic NOD mice followed by
intraperitoneal injection of blocking Ab against MDC
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Figure 2
Memory phenotype and clinical diabetogenic potential of CCR4-
bearing T cells. (a) Memory/effector phenotype of CCR4-expressing
CD4+ T cells. To assess and characterize the in vivo immunopheno-
type of CCR4+CD4+ T cells, flow cytometry of CD4+ T cells from the
spleen and panLN’s of 10- to 12-week-old NOD mice (n = 3) was per-
formed. Values for CD25, CD27, CD45RB, CD62L, CD69, and
CCR4 expression were determined by FACS analysis. We found that
CCR4-expressing CD4+ T cells have a memory/effector phenotype.
(b) Systemic expansion of pathogenic CCR4-expressing CD4+ T cell
populations in lymphoid organs. To verify the clinical significance of
CCR4-bearing CD4+ T cells in vivo, the CCR4-positive pathogenic
population was monitored by FACS analysis during disease progres-
sion in NOD mice. Six-week-old and 12-week-old prediabetic mice
and 16-week-old diabetic mice are shown. Squares mark the
CCR4high population. The CCR4-bearing population was expanded
in the secondary lymphoid tissues such as spleen and panLN’s of
NOD mice during the diabetic or prediabetic state. The data shown
are representative of three separate experiments.
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(rabbit IgG, 250 µg/mouse), (13), or the same amount
of intraperitoneal control Ab (rabbit IgG; Pierce, New
York, New York, USA) on days 0, 4, 7, 10, and 14. An
estimation of the percentage of CCR4+CD4+ T cells
within the infiltrates in pancreas, spleen, and pancre-
atic lymph nodes (panLN’s) and in circulating blood
was made by flow cytometry and histologic analyses on
days 7 and 14 after adoptive transfer. To determine the
role of anti-MDC blocking Ab in the development of
diabetes, blood glucose measurements were performed
7 days after Ab injection.
Cytokine ELISA and proliferative responses. Splenocytes or
CCR4-sorted CD4+ T cells were resuspended in serum-
free HL-1 medium. To measure antigen-specific prolif-
erative responsiveness, cells were incubated with or
without culture medium containing GAD65 that was
produced and isolated as previously described (18).
CD4+ T cell–depleted irradiated (15 Gy) splenocytes
from NOD mice were used as APCs. As a nonspecific
stimulation, splenocytes were incubated in microplates
precoated with anti-CD3 and/or anti-CD28 mAb’s. At
days 2–4, supernatants from these cultures were col-
lected and analyzed for IL-2, IL-4, and IFN-γ by ELISA.
Following incubation for 18 hours with 1 µCi/well
[3H]thymidine (Amersham Pharmacia Biotech Inc., Pis-
cataway, New Jersey, USA), cells were harvested and
[3H]thymidine incorporation was measured in a scintil-
lation counter. The results were expressed as a stimula-
tion index, which was determined by dividing total
counts from wells with antigen or Ab’s by background
counts from wells lacking antigen or Ab’s.
Analysis of islet-specific CD4 cells by flow cytometry. The
endogenous CCR4-expressing CD4+ T cells of MDC-TG
NOD mice and NOD recipients injected by anti-MDC
blocking Ab were identified for T cell homing and 
tissue distribution by flow cytometry. Pancreas,
panLN’s, spleen, Peyer’s patches, and mesenteric LNs
were teased into suspensions. The suspended cells 
(1 × 106 cells) were stained for the indicated surface
markers. Gating on 10,000 cells using a FACScan flow
cytometer (Becton, Dickinson and Co.) generated the
histograms and dot plots.
Assessment of diabetes. The development of diabetes was
assessed weekly by blood glucose measurements using
the one-step Bayer Glucometer Elite (Bayer Corp.,
Elkhart, Indiana, USA). Animals were considered dia-
betic after two consecutive glucose values greater than
300 mg/dl were measured.
Immunohistochemical and histologic analyses. Tissue sec-
tions were stained with hematoxylin and eosin (H&E)
for histologic evaluation or prepared for immunocyto-
chemical techniques as described (12). Paraffin-embed-
ded pancreata or panLN’s were stained by the indirect
immunoperoxidase method using a polyclonal rabbit
anti-mouse MDC Ab (obtained from ICOS Corp.).
Frozen sections were stained with hamster anti-mouse
TARC mAb (ICOS Corp.). H&E-stained sections were
graded for the presence of insulitis as follows: 0,
absence of inflammation; 1, presence of less than 20%
insulitis; 2, presence of 20–50% insulitis; or 3, presence
of 50–100% insulitis (12). By taking an average of the
grade of insulitis we derived an insulitis score repre-
senting the overall severity of inflammation.
Statistical analysis. Significant differences were deter-
mined by Student t test (paired or unpaired) and log
rank test using StatView software (Abacus Concepts
Inc., Berkeley, California, USA). A value of P < 0.05 was
taken as indication of significance.
Results
Functional responsiveness of CCR4-positive T cells to murine
MDC. Previous studies demonstrated a high degree of
sequence homology and similar binding characteristics
and tissue distribution between human and mouse
CCR4 (19, 20). The antigenic similarity of CCR4
between human and mouse has allowed us to validate
the use of anti-human CCR4 mAb for the analysis of
murine CCR4. We obtained and tested the anti-human
CCR4 mAb for cross-reactivity with mouse CCR4. The
Ab was used to sort CCR4-positive and -negative T cells
from BDC2.5 NOD mice. To determine whether CCR4-
positive T cells (sorted using the anti-human CCR4
mAb) could respond to the mouse CCR4 ligand MDC,
we performed a migration assay using murine MDC as
a chemoattractant for CCR4-expressing cells. As shown
in Figure 1a, we confirmed that CCR4+CD4+ T cells
obtained by sorting BDC2.5 CD4+ T cells with anti-
human CCR4 mAb showed a comparatively high
migratory capacity in response to the MDC chemoat-
tractant (migration: 14.7%, n = 3). In contrast, the
absence of CCR4 in CD4+ T cells resulted in a remark-
able absence of migration against an MDC gradient
(migration: 0.2%). Additionally, there was a blockade in
the chemotactic response of murine CCR4-positive
cells to murine MDC when engaged by anti-human
CCR4 mAb before migration (migration: 0.1%), where-
as no significant reduction was observed in the migra-
tion of CCR4-positive cells treated with isotype control
(mouse IgG1) (migration: 14.3%).
In addition, we evaluated the chemotactic function
of the CCR4 ligands murine MDC and murine TARC
as well as other chemokines, murine SLC and murine
MCP-1, on resting/naive BDC2.5 CD4+ T cells. We
found that the conditioned medium containing
murine MDC and murine TARC significantly induced
the migration of CCR4-positive CD4+ T cells (MDC,
4.7%; TARC, 4.2%, n = 3) (21); however, less migration
was observed against SLC chemoattractant (3.0%, 
n = 3). There was no significant effect on migration of
CCR4+CD4+ T cells in response to MCP-1 (0.7%, n = 3)
(Figure 1a), since this chemokine attracts CCR2-
expressing monocytes (22) as well as activated and
memory T cells, including Th1 and Th2 cells (6–8).
This indicates cross-reactivity between human and
murine CCR4 and validates the use of the anti-human
mAb’s to study murine CCR4.
We also found that the anti-human CCR4 Ab’s, which
was raised in BALB/c mice, fails to recognize CCR4-
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expressing T cells from this strain (data not shown).
However, the anti-human mAb cross-reacts with CCR4
from C57BL/6 (15) and NOD mice. We propose that
anti–human CCR4 mAb will be useful in elucidating
the role of murine CCR4 in mouse models of human
autoimmune disease. Therefore, we first asked whether
CCR4 expression could be differentially modulated in
leukocyte subsets such as CD4+, CD8+, B220+, CD11b+,
and CD11c+ cells, or following the activation or polar-
ization of cells. In agreement with CCR4 expression pat-
terns of human leukocytes (16), we demonstrated that
our anti-CCR4 Ab showed a distinct pattern of CCR4
expression in CD4+ and CD8+ T cells, but CCR4 was not
expressed on B220+, CD11b+, or CD11c+ cells from
NOD/shi mice (Figure 1b). In addition, CD4+ T cells
acquired higher levels of CCR4 and CCR5 when they
were stimulated/activated with anti-T cell receptor/anti-
CD28 mAb’s for 4 days or polarized into Th1 and Th2
effectors in vitro (Figure 1b).
CCR4 expression on polarized Th subsets. We next asked
which subset of helper T cells expresses CCR4. Th1 and
Th2 cells were induced by culture of BDC2.5 CD4+ T
cells for 4 days in RPMI 1640 supplemented with rIL-12/
anti–IL-4 mAb (11B11 clone) and rIL-4/anti–IFN-γ
mAb (46A2 clone). We verified the polarization of Th1
and Th2 cells in vitro by comparing the intracellular
cytokine profile of the T cells. As shown in Figure 1c, it
was demonstrated that the cells capable of producing
IFN-γ as a Th1-type cytokine (15.9% positive), and no 
IL-4 (0.01%) were significantly increased by Th1 induc-
tion, whereas production of Th2-type cytokine IL-4
(3.9%) but no IFN-γ (0.01%) was seen in the polarized
Th2 cells. This indicates that Th1 and Th2 cells were well
polarized and differentiated. Our in vitro experiment
polarizing BDC2.5 T cells, which are a clonal population
of CD4+ T cells that recognize a pancreatic islet antigen,
demonstrated that Th1 and Th2 cells were positive for
CD25, CD69, and CD44, reflecting their activated state
(Table 1). Interestingly, CD4+ T cells exhibited downreg-
ulation of activation molecules CD25 and CD69 follow-
ing polarization compared with CD4+ T cells stimulated
with CD3/CD28 (day 4) (Figure 1b). Significantly, and
in contrast to earlier reports (6–10) but in accordance
with a recent report (23), we found that these Th1 and
Th2 cells both express high levels of CCR4 (Table 1),
indicating that Th1 and Th2 cells expressing CCR4 are
activated memory/effector populations in vivo.
Memory phenotype and clinical diabetogenic potential of
CCR4-bearing T cells. To further delineate the relationship
between memory/effector phenotypes and CCR4 expres-
sion in vivo, we characterized the activation and memory
markers on CD4+ T cells in the spleen and panLN’s from
NOD mice. We found high levels of CCR4 expression on
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Figure 3
Immune characteristics and homing capacity of CCR4-bearing T cells
in vivo. (a) Immunophenotype of CCR4+CD4+ T cells. CD4+ T cells
from 16- to 18-week-old diabetic NOD mice were incubated with the
indicated Ab’s and then analyzed by flow cytometry to determine the
CCR4 expression levels. Left column, CCR4– (neg); center column,
CCR4low (low); right column, CCR4high (high) populations. (b) Th1-
type cytokine production by CCR4-positive cells. CCR4-positive
(CCR4low and CCR4high) and -negative cells were cocultured with
APCs for 3 days with Con A, GAD65, and media stimulation. Cul-
ture supernatants were examined by ELISA for their cytokine profiles.
White bars, CCR4-negative cells/APCs; black bars, CCR4-positive
cells/APCs. (c) Higher frequency and severity of insulitis of pancre-
atic islets of 8- to 10-week-old NOD-scid female recipients (each
group, n = 2) 1 week after adoptive transfer of CCR4-positive and
CCR4-negative CD4+ cells.
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activated (CD25+CD69+) and memory/effector leukocyte
subsets (CD45RBlow/CD62Llow/CD27+) in the spleen and
panLN’s of NOD mice (Figure 2a). This was comparable
to the expression pattern of human leukocytes (16), indi-
cating that CCR4 expression marks the memory/effector
CD4+ T cell population in vivo. To understand the clini-
cal significance of CCR4-bearing CD4+ T cells in vivo, we
determined the proportion of CCR4+CD4+ T cells during
disease progression in 6-week-old prediabetic NOD mice
with no lymphocyte infiltration, 12-week-old prediabet-
ic NOD mice with insulitis, and 16-week-old diabetic
NOD mice (24). We demonstrated that the CCR4-bear-
ing (CCR4low and CCR4high) T cell population was signif-
icantly expanded in the secondary lymphoid tissues such
as spleen and panLN’s of NOD mice during the later pre-
diabetic (12 weeks of age) (percentage of total T cells:
spleen, 23.7%; panLN’s, 35.5%) and diabetic stage of dis-
ease (spleen, 28.6%; panLN, 35.8%) compared with that in
6-week-old prediabetic mice (spleen, 16.9%; panLN,
16.3%). A low proportion of CCR4-bearing T cells was
found in the spleens of 6- to 16-week old C57BL/6 mice
(<5%) (data not shown). Interestingly, the percentage of
CD4+ T cells that were CCR4high was remarkably
increased in the spleens (4.6-fold) and panLN’s (4.3-fold)
of diabetic NOD mice compared with younger predia-
betic mice (Figure 2b).
Immune characteristics and homing capacity of CCR4-bearing
T cells in vivo. CCR4 expression marks a diabetogenic pop-
ulation of activated/memory autoimmune T cells in vivo
(Figure 2). Memory CD4+ T cells primarily reside in or cir-
culate through the spleen (25). From these findings, we
investigated the in vivo activation/memory status and
immunophenotype of CCR4+CD4+ T cells from the
spleen of diabetic NOD mice 16–18 weeks old. We divid-
ed splenic CD4+ populations into three categories of
CCR4 expression according to the criteria for human
CCR4 expression (26): CCR4low (45.7%), CCR4high (35.0%),
and CCR4-negative (19.3%) populations (Figure 3a).
Strikingly, the CCR4-positive population exclusively com-
prises CD44high/med cells, whereas the CCR4-negative pop-
ulation includes the CD44low cells. It seems likely that
CCR4high/CD44high CD4+ T cells are the in vivo patho-
genic population, considering the recent finding that
injection of anti-CD44–blocking mAb induces resistance
to insulin-dependent diabetes mellitus (27). The majori-
ty of splenic CD4+ T cells were CD25low/CD69low/
CD45RBlow cells, irrespective of the presence of CCR4
(Figure 3a, top), reflecting that the spleen is a major site
for the residence of memory T cells (25). Furthermore, the
CCR4high population expressed higher levels of ICAM-1
(CD54), MHC class I, and CD95 than did CCR4-negative
cells (Figure 3a). Cumulatively, these results indicate that
the CCR4-positive populations in vivo are cells with a
memory phenotype that harbor stronger cell adhesion
capabilities than are found on  CCR4-negative cells. In
addition, CCR4-positive T cells displayed Th1-cytokine
production (IFN-γ and IL-2) when cocultured with APCs
upon Con A stimulation (Figure 3b). Interestingly, mas-
sive aggregation between CCR4-positive CD4+ T cells and
APCs upon Con A stimulation was followed by Th1-type
cytokine production, whereas cytokine production and
heterotypic aggregation were not found in the coculture
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Figure 4
CCR4 induction following in vitro CD3/CD28 stimulation. (a) Sort-
ed CCR4–CD4+ T cells purified from spleens of 16- to 18-week-old
diabetic NOD mice were analyzed for expression of CCR4 and acti-
vation markers following in vitro CD3/CD28 stimulation. CCR4-neg-
ative cells were incubated in vitro for 2 days in the presence or
absence of anti-CD3/anti-CD28 mAb’s. The majority of CCR4-neg-
ative populations induced CCR4 expression following stimulation
with anti-CD3/anti-CD28 mAb’s. These CCR4-positive cells also
expressed CD25 and high levels of CD44 and CD69. Open area,
media stimulation; filled area, anti-CD3/anti-CD28 stimulation. (b)
The culture supernatants generated from CD3/CD28-stimulated
(black bars) and media-stimulated cells (white bars) were analyzed
for IL-2, IFN-γ, and IL-4 by ELISA.
Table 1
CCR4 expression on polarized Th subsets
Expression (%)
Marker Th1 Th2
Vβ4+CD4 99.7 98.6
CCR4 98.3 99.7
CD25 99.0 99.7
CD44low+med 21.2 51.6
CD44high 78.9 48.3
CD69 99.8 99.6
CD62L 22.2 8.4
Immunophenotypic analysis of in vitro polarized BDC2.5 Th1 and Th2 cells. Val-
ues for CD25, CD44, CD69, CD62L and CCR4 expression on Th1 and Th2 cells
were determined by FACS analysis. Th1 and Th2 cells both expressed CCR4.
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of CCR4-negative T cells and APCs upon Con A stimula-
tion (data not shown).
To further determine whether these CCR4-positive cells
have a stronger cell migratory capacity than CCR4-nega-
tive cells, CCR4-positive and -negative T cell populations
were sorted from spleen cells of 16- to 18-week-old dia-
betic NOD mice and injected into 8- to 10-week-old
immunodeficient recipients. As shown in Figure 3c and
Table 2, these adoptive transfer studies using CCR4-
expressing T cells demonstrated a higher frequency of
insulitis in pancreatic islets of NOD-scid recipients 1
week after transfer (mean score for insulitis: 1.68 ± 0.165,
total islets: 105) than was found in recipients of CCR4-
negative T cells (mean score for insulitis: 0.22 ± 0.015;
total islets: 124) (n = 3, P = 0.001). This suggests that
CCR4-positive cells harbor islet-homing capability.
CCR4 induction following in vitro CD3/CD28 stimulation.
We next asked whether CCR4 acquisition correlates
with the activation status of cells stimulated by T cell
receptor and costimulatory molecule ligation. In vitro
experiments to evaluate the characteristics of these
cells revealed that CCR4 expression was induced on
the majority of T cells when purified CCR4–CD4+ T
cells (Figure 3a) from NOD mice were stimulated with
anti-CD3 and anti-CD28 mAb’s (Figure 4a), suggest-
ing that CD4+ T cells upregulate CCR4 following T cell
receptor/CD28 signaling. Concomitantly, high levels
of the Th1 cytokines (IFN-γ and IL-2) but not Th2
cytokines were expressed by these CCR4-negative cells
following stimulation by anti-CD3 and anti-CD28
engagement (Figure 4b).
TARC expression in pancreatic islets of prediabetic NOD mice.
We sought to determine whether the CCR4 ligands
MDC (21, 28) and TARC (29) are upregulated by the
NOD pancreas, whose infiltrating cells are known to
include dendritic cells, macrophages (2, 30), and activat-
ed B cells (31, 32) as cellular sources for these factors at
the initial stages of development of diabetes (24). Using
immunolocalization techniques, we identified TARC-
expressing cells in the infiltrated islets of 10- to 14-week-
old prediabetic NOD mice but not in normal islets of 6-
to 8-week-old NOD mice (n = 3) (Figure 5a), strengthen-
ing the in vivo relevance of the CCR4 pathway in the
development of diabetic pathogenesis. Unlike TARC-
expressing cells,  MDC-expressing cells were not readily
detected in the infiltrated islets.
Attenuation of autoimmune diabetes by Ab’s to MDC. MDC
has been described as a functional ligand for the
chemokine receptor CCR4 (21), and we demonstrated
that CCR4-expressing T cells distinguish potentially
pathogenic populations harboring a potent islet-hom-
ing capacity. According to a recent report (33), neutral-
ization of MDC with specific rabbit polyclonal Ab’s
effectively prevented interstitial lung inflammation and
development of airway hypersensitivity by regulating the
migration and accumulation of leukocytes within the
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Table 2
High frequency of insulitis caused by CCR4+CD4+ T cells
CCR4 Number of Grade of insulitis Insulitis
expression total islets 0 1 2 3 score
% NE % NE % NE % NE
– 105 78.1 82 21.9 23 0 0 0 0 0.22 ± 0.015
+ 124 20.2 25 28.2 35 15.3 19 36.3 45 1.68 ± 0.165
Sorted CCR4-positive and -negative CD4+ cells from NOD mice (16–18 weeks old) were adoptively transferred into 8- to 10-week-old NOD-scid recipients 
(n = 3, P = 0.001). One week after adoptive transfer, H&E-stained pancreas sections were scored for the presence of insulitis as described in Methods. P values
were calculated by unpaired Student t test. NE, numbers of islets examined; %, the percentage of islet numbers examined among total islet cells.
Figure 5
TARC and MDC expression in pancreatic islets and lymph nodes of pre-
diabetic NOD mice. (a) The CCR4 ligand TARC was expressed at low
levels by infiltrating cells (right, arrow) in pancreatic islets of 10- to 14-
week-old prediabetic NOD mice, but not in the normal islets of 6- to 8-
week-old NOD mice (left). (b) MDC was distinctly expressed in the
panLN’s of NOD/shi mice (right), but not in B57BL/6 NOD mice (left).
Arrows indicate MDC-positive cells in the T cell area (T) but not in the
follicle (F). (c) MDC was strongly expressed in pancreatic islets of MDC-
TG mice (right), but not in non-TG NOD mice (left).
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tissues. To determine the role of CCR4 engagement on
the severity of insulitis and diabetes, neutralizing Ab’s
against MDC were injected on days 0, 3, 7, 10, and 14
into NOD-scid mice that had received splenocytes from
diabetic NOD mice on day 0. Thereafter, mice were ana-
lyzed for the proportion of CCR4+CD4+ T cells in the
pancreas and for severity of insulitis by flow cytometry
and histologic analyses, respectively, on day 7 and day 14,
respectively. The specific inhibition of MDC caused a sig-
nificant decrease (2.5-fold) in the proportion of these 
T cells in panLN’s after 1 week, whereas no difference
was found in the spleen, pancreas and blood (n = 3) (Fig-
ure 6a). We found that MDC was distinctly expressed on
the large cells in the T cell area (T) but not in the follicle
(F) of panLN’s from 12-week-old prediabetic NOD/shi
mice, while no MDC-positive cells were observed in age-
matched control B57BL/6 mice (Figure 5b). This is in
agreement with previous reports that MDC is distinctly
expressed by dendritic cells within the T cell zone drain-
ing into LNs, and that acquisition of MDC responsive-
ness is an early event during in vivo antigen-specific T
cell activation (34–36). This suggests that at early stages
of the response, LNs are the primary sites in which MDC
acts to control recruitment of CCR4-expressing T cells. 
However, during later stages of our MDC inhibition
experiment (at 14 days), the proportion of CCR4-positive
cells was significantly decreased in the target pancreas
(2.3-fold) and circulating blood (1.9-fold), while LNs and
spleen no longer demonstrated the reduced proportion
of T cells (Figure 6a). MDC blockage also resulted in a
remarkable decrease (6.6-fold) in the absolute number of
CCR4+CD4+ T cells after 1 week and 2 weeks (8.9-fold)
within the pancreatic infiltrates compared with control
Ab–treated mice (n = 3) (Figure 6b). In accordance with
the findings in Figure 6, a and b, neutralization of MDC
ultimately prevented accumulation of CCR4-expressing
T cells in the pancreatic islets compared with rabbit
IgG–treated mice (Table 3). On weeks 1 and 2 after cell
transfer, mice treated with anti-MDC Ab had signifi-
cantly reduced levels of insulitis (mean score for insulitis:
1 week, 0.21 ± 0.04; 2 weeks, 0.60 ± 0.05, P = 0.011, n = 3)
compared with control group mice (1 week, 0.70 ± 0.05;
2 weeks, 2.08 ± 0.14, P = 0.021, n = 3). 
Finally, we determined whether MDC neutralization
could affect disease onset. This experiment must be pre-
sented with the caveat that the last anti-MDC treatment
occurs on day 14, after which the concentration of this
reagent in vivo is expected to decline. Interestingly how-
ever, Figure 6c shows that MDC neutralization indeed
resulted in reduced incidence of diabetes (25% of anti-
MDC treated mice were diabetic by 40 ± 2 days, n = 5)
compared with control rabbit IgG–treated mice (75%
had diabetes at 38 ± 2 days, n = 5) (P = 0.041). This data
supports a role for CCR4 engagement by MDC in the
expansion/activation of “central” memory T cells in the
lymph nodes and subsequently for further expansion of
memory/effector cells in the spleen and homing of effec-
tor T cells into the pancreas during development of
insulitis and diabetes.
Intensive recruitment of CCR4-bearing T cells by MDC. Hav-
ing determined that Th1-polarized islet antigen-specific
cells express CCR4 and that CCR4-bearing T cells exhib-
it a memory phenotype and strong islet-homing poten-
tial, we sought to determine whether CCR4-expressing 
T cells precipitate disease. It was reported that the two
functional ligands for CCR4, MDC and TARC, are encod-
ed on human chromosome 16 and have overlapping
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Figure 6
Attenuated disease onset and insulitis frequency after MDC blockage.
The effect of anti-MDC blocking Ab on the development of diabetes
was determined using a specific neutralizing Ab against MDC. Flow
cytometry analysis was performed on days 7 and 14 after adoptive cell
transfer. (a) Percentage of CCR4+CD4+ T cells infiltrating the panLN’s,
pancreas, and spleen and in the circulating blood (n = 3). (b) The
absolute cell number of pancreas-infiltrating and panLN CCR4+CD4+
T cells. Control group, black bars (n = 3); blocking Ab group, white bars
(n = 3). (c) Attenuated disease onset after MDC blockage. Open circles,
control group (n = 5); filled circles, blocking Ab group (n = 5). Seventy-
five percent of anti-MDC Ab-treated mice were diabetic by 38 ± 2 days;
25% of control rabbit IgG–treated mice were diabetic at 40 ± 2 days, 
P = 0.041. This data supports a role for CCR4 engagement in the devel-
opment of insulitis and diabetes.
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chemotactic properties (30). To elicit increased recruit-
ment of CCR4-bearing T cells to the pancreas, we engi-
neered NOD mice to express the CCR4 ligand MDC in
the pancreas (Figure 5c). These MDC-expressing pancre-
ata of 12-week-old NOD mice contained a 2.6-fold high-
er percentage (Figure 7a, bottom) and 5.7-fold higher
absolute number (Figure 7b) of CCR4-expressing CD4+
T cells in the pancreas than did non-TG NOD littermates
(n = 3). However, no difference was found in the propor-
tion of CCR4+CD4+ T cells in the spleen, panLN’s (Figure
7a, bottom), Peyer’s patches, or mesenteric LNs (data not
shown). Interestingly, as demonstrated in Figure 7c,
MDC expression promoted the intensive recruitment not
only of CCR4-expressing CD8+ T cells (9.2-fold), but also
of APCs, which include CCR4– B220+ cells (11.5-fold),
CCR4–CD11b+ macrophages (9.2-fold), and CD11c+ den-
dritic cells (6.4-fold). This finding was further supported
by assessing the severity of insulitis in pancreatic islets
from 9- to 11-week-old MDC-TG mice (insulitis grades:
0, 17.0%; 1, 19.5%; 2, 15.5%; 3, 48.0%; total islets, 123) com-
pared with age-matched non-TG NOD mice (insulitis
scores: 0, 39.1%; 1, 40.2%; 2, 9.2%; 3, 11.5%; total islets, 87)
(n = 3, P < 0.01) (data not shown).
MDC-mediated acceleration of disease. To assess the
impact of this process on disease, we compared the
clinical onset of disease in MDC-TG mice with their
non-TG NOD littermates. As seen in Figure 8a, the
intensive accumulation of CCR4-expressing T cells
and APCs (Figure 7) accelerated the development of
disease: 50% of MDC+ mice were diabetic by 142 ± 17
days, compared with 50% diabetes at 238 ± 30 days in
MDC– mice (P = 0.017). We also examined whether
MDC-mediated recruitment enhances the diabeto-
genic capacity of T cells by performing adoptive trans-
fer experiments, injecting splenocytes from MDC-
NOD mice into NOD-scid recipient mice. As
demonstrated in Figure 8b, splenocytes from predia-
betic MDC-TG mice (8 weeks old) accelerated disease
dramatically compared with splenocytes from non-
TG NOD mice (25% disease onset at 70 ± 19 days and
50% at 77 ± 5 days with splenocytes from MDC-TG
donors; 25% at 104 ± 18 days with splenocytes from
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Table 3
Effect of anti-MDC Ab on frequency of insulitis
Time since Ab injected Cells transferred Number of Number Grade of insulitis Insulitis
cell transfer (i.p.) (×107, i.v.) total islets of mice 0 1 2 3 score
% NE % NE % NE % NE
1 wk Rabbit IgG 1.5 96 2 51.0 49 34.4 33 8.3 8 6.3 6 0.70 ± 0.05
Anti-MDC Ab 120 2 80.8 97 17.5 21 1.7 2 0 0 0.21 ± 0.04A
2 wks Rabbit IgG 1.5 90 2 11.1 10 22.2 20 14.4 13 52.2 47 2.08 ± 0.14
Anti-MDC Ab 82 2 54.9 45 34.1 28 7.3 6 3.7 3 0.60 ± 0.05B
The influence of MDC neutralization on insulitis was determined. Diabetic NOD splenocytes were transferred into NOD-scid mice followed by injection of anti-
MDC blocking Ab’s (n = 3) or control rabbit IgG (n = 3) on days 1, 3, 7, and 10. One week and 2 weeks after cell transfer, H&E-stained pancreas sections were
scored for the presence of insulitis as described in Methods. P values were calculated by unpaired Student t test. MDC neutralization significantly suppressed
the infiltration of cells into pancreatic islets. AP = 0.011; BP = 0.021. i.p., intraperitoneally; i.v., intravenously; NE, number of islets examined; %, the per-
centage of islet numbers examined among total islet cells.
Figure 7
Intensive recruitment of CCR4-bearing T cells by MDC. The effect of MDC on the recruitment of CCR4-bearing CD4+ T cells and APCs to
the pancreas was analyzed in MDC-TG (black bars, n = 3) and non-TG NOD mice (white bars, n = 3) by FACS. (a) Percentage and (b) absolute
cell number of pancreas-infiltrating CCR4+CD4+ T cells. (c) Absolute number of CCR4+CD8+ T cells and APCs that infiltrated pancreas.  Data
shown are representative of three separate experiments.
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Non-TG donors; P = 0.005). This indicates that the
enhanced recruitment of CCR4-expressing T cells
magnifies their pathogenicity. Not surprisingly, we
also observed higher amounts of IFN-γ but not IL-4
when MDC-TG splenocytes were stimulated with
GAD65 presented by APCs, indicating increased Th1
autoimmunity (Figure 8d). Interestingly, there were
no differences in MDC-mediated T cell proliferation
upon stimulation with GAD65 presented by APCs
(Figure 8e) and engagement of anti-CD3 and anti-
CD28 Ab’s (Figure 8f). We suggest that the recruit-
ment of CCR4-bearing T cells into pancreatic islets
intensifies Th1 immune responses, independent of
the marked expansion of these T cells.
Discussion
We demonstrate in this study that CCR4 expression
marks a pathogenic population of autoimmune T cells
participating in the development of tissue-driven autoim-
mune reactions. The CCR4-bearing pathogenic T cell
population was extensively expanded in the secondary
lymphoid tissues such as spleen and panLN’s of NOD
mice during the progression of autoimmune diabetes,
implying that spleen and panLN’s are the sites for in vivo
expansion and maintenance of the diabetogenic T cell
population. An increase in the CCR4-positive population
in spleen and panLN’s of 12-week-old prediabetic NOD
mice may reflect the tight relationship between expan-
sion of the pathogenic T cell pool in the secondary lym-
phoid organs and the onset of insulitis. This suggests
that the CCR4-positive T cell population might be sys-
temically expanded through antigenic stimulation in the
lymphoid organs and subsequently infiltrates the target
islets. In spite of extensive and active insulitis, intact β
cells persist for long periods and no diabetes occurs, indi-
cating the uncoupling of insulitis and diabetes. The
molecular mechanisms and factors underlying the tran-
sition between passive insulitis and diabetes are unclear
(37). Here we demonstrate an increase in the number of
CCR4high T cells in the spleen of diabetic NOD mice (16
weeks old), compared with prediabetic (6 weeks and 12
weeks old) mice. This suggests that the transition accom-
panies the acquisition of pathogenic potential by
CCR4high lymphoid populations, which controls the
switch from insulitis to overt diabetes through the acqui-
sition of new effector capabilities.
In the system used here, Th1 and Th2 cells were max-
imally polarized and activated (CD25+CD69+CD44high)
to express their characteristic cytokine profiles, yet
both subtypes expressed CCR4, in contrast to several
recent reports (6–10). This distinction could represent
species differences or a different degree of differentia-
tion/activation between cells used in the experiments
described here and those used by other investigators.
Chemokines produced in vivo at the sites of inflam-
mation are likely to play a major role in the recruitment
of particular cell types that infiltrate and participate in
the pathological lesions. Presumably the differential
expression of chemokine receptors may discriminate
pathogenic T cells within bulk populations. Based on
the observations that cells expressing the functional lig-
and for CCR4, TARC, were detected within infiltrated
islets from prediabetic mice and that pancreatic MDC
expression induced intensive recruitment of CCR4-pos-
itive cells and accelerated disease, we speculate that
TARC or MDC is an initial signal as well as a modulator
for recruitment and maintenance of antigen-specific 
T cell populations through T cell–APC interactions in
target tissues (2, 11, 30–32). It was reported that MDC
(34–36) and TARC (38) are constitutively expressed by
dendritic cells in T cell areas of lymph nodes for the pref-
erential recruitment of antigen-specific activated T cells
through T cell–dendritic cell interactions. In the present
study, MDC neutralization experiments (Figure 6)
showed that LNs are the primary sites for the initial in
vivo expansion of diabetogenic CCR4-positive T cells.
Therefore, it is plausible that the CCR4 ligands TARC or
MDC can play a dual role in the non-lymphoid as well as
lymphoid organs: they can assume an inflammatory role
when produced in the target organ and can also partici-
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Figure 8
MDC-mediated acceleration of disease. (a) Acceleration of diabetes in
MDC-TG NOD mice. Diabetogenic potential was compared after
adoptive transfer of splenocytes from (b) 8-week-old prediabetic (n = 3)
or (c) 16- to 18-week-old diabetic (n = 3) MDC-TG and non-TG litter-
mates into 8- to 10-week-old NOD-scid female recipients. Open cir-
cles, non-TG NOD littermates; filled circles, MDC-TG NOD mice. (d)
MDC-mediated Th1 immune response. Splenocytes from 11-week-old
MDC-TG and non-TG NOD females (three mice/group) were stimu-
lated with the islet antigen, GAD65, presented by irradiated spleen cells
as APCs. Culture supernatants were analyzed for cytokine secretion by
ELISA. T cell proliferation was measured in response to GAD65 pre-
sented by APCs (e) or upon stimulation of costimulatory factors such
as CD3/CD28 (f). Bars represent mean values ± SEM from two sepa-
rate experiments. White bars and open circles, non-TG littermates.
Black bars and filled circles, MDC-TG NOD females. 
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pate in the regulation of cell-cell interactions leading to
lymphoid expansion in secondary lymphoid organs.
The interaction between CCR4 and MDC (or TARC)
has been described as the primary requirement for in
vivo biological phenomena such as recognition of
memory T cells (39), cell migration (9), T cell develop-
ment in the thymus (13), and dendritic cell maturation
(34). However, little was known about the role of
CCR4-dependent migration during autoimmune
pathogenesis. This study demonstrated that CCR4-
expressing T cells exhibited a remarkable homing
capacity (Figure 3 and Table 2) accompanied by hyper-
expression of adhesion/activation molecules (ICAM-1,
MHC class I, CD95, and CD44) on their cell surface.
Therefore, it appears that activation signals through 
T cell receptor/CD28 provided by APCs render T cells
competent for recruitment to sites of immune and
inflammatory reactions as well as Th1 cytokine secre-
tion and firm adhesion through upregulation of
CCR4 and adhesion/activation molecules, suggesting
an inflammatory cascade in the diabetogenic pancreas.
Thus, CCR4-positive T cell populations require APC
participation for attaining their effector phenotype
and eliciting Th1 immunity.
In addition, the enhanced recruitment of CCR4-bear-
ing cells and APCs in NOD mice via expression of the
ligand MDC resulted in acceleration of clinical disease.
Interestingly, while 9-week-old MDC-TG NOD mice
showed a significant increase in CD4+ and CD8+ T cell
accumulation, the numbers of APCs were comparable
to those in non-TG mice (data not shown). Therefore,
we propose that CCR4-bearing T cells with an activat-
ed memory phenotype home to the pancreatic islets,
affecting the pancreatic microenvironment, which sub-
sequently allows the recruitment of newly arriving
CCR4-expressing T cells as well as APCs such as B cells,
dendritic cells, and macrophages. We suppose a sce-
nario explaining an amplified cascade of CCR4-bearing
T cells and APC accumulation by MDC. Accumulated
CCR4-bearing T cells secrete multiple “inflammatory”
chemokines (40), especially MCP-1 (2, 41), and these
molecules are able to function as ligands for particular
types of cells expressing appropriate chemokine recep-
tors to recruit the pancreatic islets. We suggest that the
CCR4/TARC (or MDC) axis plays an initial role in
recruitment of pathogenic T cells and subsequently
provides an amplified inflammatory cascade in the dia-
betogenic pancreas through continuous T cell–APC
interactions. Combined with the accelerated disease
transfer in the NOD-scid model, the presence of MDC
appeared to amplify antigen-specific diabetogenicity of
T cells, which become pathogenic populations in vivo.
We found that a small proportion of the CCR4-negative
splenic T cell population was memory cells (CD45RBlow)
(Figure 2a), indicating that the CCR4– phenotype of CD4+
T cells found in the target pancreas after adoptive spleno-
cyte transfer (Figure 6a) might be related to transferring
CCR4-positive as well as CCR4-negative memory CD4+
T cells. We also observed that CD4 downregulation was
induced in the pancreas-infiltrating CD4+ T cells, while no
downregulation of other cell type–specific surface markers
such as CD8, B220, CD11b, or CD11c in NOD/shi mice
was detected (data not shown). This could be due to a
counterregulatory mechanism acting on autoreactive
CD4+ T cells in the inflamed tissues.
From the data presented we conclude that CCR4-pos-
itive cells possess disease-causing potential due to
increased cell migratory capacity and an ability to
establish firm contact between T cells and APCs, imply-
ing that CCR4-expressing cells are the authentic path-
ogenic population in vivo. Thus, CCR4 may be a con-
tributing factor in facilitating the migration of
autoimmune pathogenic T cell populations.
We suggest that CCR4-bearing T cells participate in
autoimmune pathogenesis by eliciting the migration
of antigen-specific memory T cell effectors. Modula-
tion of the CCR4-bearing population may reduce the
inflammatory response by allowing rapid clearance of
pathogenic cells from the lesion. From this point of
view, manipulation of CCR4-expressing T cells could
comprise a potential target for the treatment of inflam-
matory disorders.
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